Abstract
Analyzing drug-treated and mutant yeast cells with the new tools of genomics enables the identification of drug targets and should improve the odds of developing useful therapeutics ( pages 1293–1301 ).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Marton, M.J. et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature Med. 4 , 1293–1301 (1998).
DeRisi, J.L., Iyer, V.R. & Brown, P.O. Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 278, 680– 686 (1997).
Wodicka, L., Dong, H., Mittmann, M., Ho, M.-H. & Lockhart, D.J. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nature Biotechnol. 15, 1359 –1367 (1997).
Cho, R.J. et al. A genome-wide transcriptional analysis of the mitotic cell cycle. Mol. Cell 2, 65–73 (1998).
Shoemaker, D.D., Lashkari, D.A., Morris, D., Mittmann, M. & Davis, R.W. Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel bar-coding strategy. Nature Genet. 14, 450–456 (1996).
Gray, N.S. et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533–538 (1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lockhart, D. Mutant yeast on drugs. Nat Med 4, 1235–1236 (1998). https://doi.org/10.1038/3212
Issue Date:
DOI: https://doi.org/10.1038/3212
